FDA clears Myriad's ovarian cancer test

By LabPulse.com staff writers

May 11, 2020 -- Myriad Genetics has received clearance from the U.S. Food and Drug Administration (FDA) for use of its myChoice CDx test for identifying advanced ovarian cancer in patients with positive homologous recombination deficiency status.

The clearance allows clinicians to use the test in women who are eligible for treatment with olaparib (Lynparza, Merck/AstraZeneca) in combination with bevacizumab (Avastin, Roche), the company said. Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor developed by AstraZeneca and Merck; Myriad has been collaborating with AstraZeneca since 2007 to develop companion diagnostics for Lynparza, according to the firm.

Myriad Genetics touts results from depression studies
Myriad Genetics is touting the results of a meta-analysis that show the company's GeneSight Psychotropic test significantly improves clinical outcomes...
Myriad withdraws fiscal 2020 guidance, updates practices
Myriad Genetics will not issue financial guidance for the 2020 fiscal year due to unpredictable effects of the global COVID-19 pandemic.
Myriad files companion BRCA test in prostate cancer
Myriad Genetics' BRACAnalysis companion diagnostic for the drug olaparib (Lynparza) is headed for a new indication in prostate cancer, following the filing...
Lynparza PARP approval opens door to more pancreatic cancer testing
Approval of the drug olaparib (Lynparza, Merck/AstraZeneca) by the U.S. Food and Drug Administration at the end of 2019 paves the way for more testing...
Myriad opens hood on carriers of breast cancer risk genes
Myriad Genetics plans to offer more risk prediction information to women who carry mutations associated with breast cancer. Results from a validation...

Copyright © 2020 LabPulse.com

Last Updated ls 5/11/2020 11:57:02 AM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email